Kiora Pharmaceuticals (KPRX) Competitors $2.66 +0.06 (+2.31%) Closing price 04/11/2025 03:59 PM EasternExtended Trading$2.72 +0.05 (+2.07%) As of 04/11/2025 07:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock KPRX vs. COEP, OSTX, ALGS, ESLA, NRXP, MRNS, LTRN, LVTX, AKTX, and ALLKShould you be buying Kiora Pharmaceuticals stock or one of its competitors? The main competitors of Kiora Pharmaceuticals include Coeptis Therapeutics (COEP), OS Therapies (OSTX), Aligos Therapeutics (ALGS), Estrella Immunopharma (ESLA), NRx Pharmaceuticals (NRXP), Marinus Pharmaceuticals (MRNS), Lantern Pharma (LTRN), LAVA Therapeutics (LVTX), Akari Therapeutics (AKTX), and Allakos (ALLK). These companies are all part of the "pharmaceutical products" industry. Kiora Pharmaceuticals vs. Coeptis Therapeutics OS Therapies Aligos Therapeutics Estrella Immunopharma NRx Pharmaceuticals Marinus Pharmaceuticals Lantern Pharma LAVA Therapeutics Akari Therapeutics Allakos Coeptis Therapeutics (NASDAQ:COEP) and Kiora Pharmaceuticals (NASDAQ:KPRX) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, community ranking, earnings, media sentiment, valuation, institutional ownership, profitability, risk and analyst recommendations. Which has more volatility and risk, COEP or KPRX? Coeptis Therapeutics has a beta of -0.68, indicating that its stock price is 168% less volatile than the S&P 500. Comparatively, Kiora Pharmaceuticals has a beta of -0.53, indicating that its stock price is 153% less volatile than the S&P 500. Which has stronger earnings & valuation, COEP or KPRX? Kiora Pharmaceuticals has higher revenue and earnings than Coeptis Therapeutics. Coeptis Therapeutics is trading at a lower price-to-earnings ratio than Kiora Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCoeptis TherapeuticsN/AN/A-$21.27M-$5.80-1.62Kiora Pharmaceuticals$16M0.50-$12.51M$1.042.56 Do institutionals & insiders believe in COEP or KPRX? 13.9% of Coeptis Therapeutics shares are held by institutional investors. Comparatively, 77.0% of Kiora Pharmaceuticals shares are held by institutional investors. 24.3% of Coeptis Therapeutics shares are held by company insiders. Comparatively, 0.9% of Kiora Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Does the media favor COEP or KPRX? In the previous week, Coeptis Therapeutics and Coeptis Therapeutics both had 1 articles in the media. Coeptis Therapeutics' average media sentiment score of 1.89 beat Kiora Pharmaceuticals' score of 0.93 indicating that Coeptis Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Coeptis Therapeutics Very Positive Kiora Pharmaceuticals Positive Do analysts rate COEP or KPRX? Kiora Pharmaceuticals has a consensus price target of $10.00, suggesting a potential upside of 275.94%. Given Kiora Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Kiora Pharmaceuticals is more favorable than Coeptis Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Coeptis Therapeutics 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00Kiora Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.50 Is COEP or KPRX more profitable? Kiora Pharmaceuticals' return on equity of 21.32% beat Coeptis Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Coeptis TherapeuticsN/A -1,094.50% -219.97% Kiora Pharmaceuticals N/A 21.32%16.39% Does the MarketBeat Community prefer COEP or KPRX? Kiora Pharmaceuticals received 13 more outperform votes than Coeptis Therapeutics when rated by MarketBeat users. However, 83.33% of users gave Coeptis Therapeutics an outperform vote while only 75.00% of users gave Kiora Pharmaceuticals an outperform vote. CompanyUnderperformOutperformCoeptis TherapeuticsOutperform Votes583.33% Underperform Votes116.67%Kiora PharmaceuticalsOutperform Votes1875.00% Underperform Votes625.00% SummaryKiora Pharmaceuticals beats Coeptis Therapeutics on 13 of the 16 factors compared between the two stocks. Remove Ads Get Kiora Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for KPRX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart KPRX vs. The Competition Export to ExcelMetricKiora PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$7.98M$6.23B$5.25B$7.52BDividend YieldN/A3.04%5.34%4.30%P/E Ratio2.566.6321.3617.69Price / Sales0.50218.18366.3293.44Price / CashN/A65.6738.1534.64Price / Book0.375.716.283.89Net Income-$12.51M$141.10M$3.19B$247.17M7 Day Performance1.53%0.11%0.66%1.77%1 Month Performance-18.40%-16.19%-11.10%-8.64%1 Year Performance-47.78%-18.28%4.51%-4.07% Kiora Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)KPRXKiora Pharmaceuticals3.2892 of 5 stars$2.66+2.3%$10.00+275.9%-51.0%$7.98M$16M2.5610Gap UpCOEPCoeptis Therapeutics0.6765 of 5 stars$9.25-4.3%N/A+9.4%$31.13MN/A-1.592Positive NewsGap UpOSTXOS Therapies2.1104 of 5 stars$1.43+2.1%$18.00+1,158.7%N/A$30.98MN/A0.00N/ANews CoverageGap UpALGSAligos Therapeutics3.9389 of 5 stars$5.05-15.1%$70.00+1,286.1%-84.6%$30.88M$3.95M-0.3890Positive NewsHigh Trading VolumeESLAEstrella Immunopharma2.2097 of 5 stars$0.85-3.4%$16.00+1,782.4%-20.3%$30.74MN/A-3.27N/APositive NewsNRXPNRx Pharmaceuticals2.582 of 5 stars$1.81+1.1%$28.25+1,460.8%-62.7%$30.62MN/A-0.852MRNSMarinus Pharmaceuticals1.9446 of 5 stars$0.55-0.2%$4.79+771.6%-93.1%$30.32M$30.99M-0.22110Analyst ForecastNews CoverageLTRNLantern Pharma1.929 of 5 stars$2.81-6.0%$25.00+789.7%-51.9%$30.31MN/A-1.5820LVTXLAVA Therapeutics2.0895 of 5 stars$1.14-1.7%$3.17+177.8%-67.4%$29.99M$11.98M-1.1160Gap UpAKTXAkari TherapeuticsN/A$1.10-1.4%N/A-9.3%$29.66MN/A0.009Upcoming EarningsAnalyst ForecastGap UpALLKAllakos4.4769 of 5 stars$0.32+1.4%$2.00+526.0%-73.5%$28.82MN/A-0.16190Positive News Remove Ads Related Companies and Tools Related Companies Coeptis Therapeutics Competitors OS Therapies Competitors Aligos Therapeutics Competitors Estrella Immunopharma Competitors NRx Pharmaceuticals Competitors Marinus Pharmaceuticals Competitors Lantern Pharma Competitors LAVA Therapeutics Competitors Akari Therapeutics Competitors Allakos Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:KPRX) was last updated on 4/12/2025 by MarketBeat.com Staff From Our PartnersControversial opinion: Volume isn't enough.Don’t be fooled by volume alone — it's just one piece of the trading puzzle. High demand doesn’t matter if sup...MillPub | SponsoredCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredDeFi Coin on Verge of Breakout!Crypto’s down — but the fundamentals aren’t. Strategic investors are using this dip to scoop up undervalued...Crypto 101 Media | SponsoredBITCOINDid you miss out on the 1000%+ gains of Bitcoin over the past 5 years? If so, you don't want to miss this.....Awesomely, LLC | SponsoredThis almost killed Elon Musk (chilling details emerge)Elon Musk's Near-Death Experience Sparks Dire Warning for Americans After cheating death twice—once in a te...Colonial Metals | SponsoredThe rotation into gold miners is on.They’re deeply undervalued gold developers with massive in-the-ground, proven resources - and now, fast-track ...Golden Portfolio | SponsoredElon Musk is helping print “new gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kiora Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Kiora Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
